Details of the Drug

General Information of Drug (ID: DMX38HQ)

Drug Name

Apomorphine

Synonyms

Apomorphine (intranasal, Parkinson's disease)

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1]
Idiopathic parkinson disease	8A00.0Z	Phase 3	[2]
Sexual dysfunction	HA00-HA01	Phase 2	[3]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

G04BE07: Apomorphine

G04BE: Drugs used in erectile dysfunction

G04B: UROLOGICALS

G04: UROLOGICALS

G: GENITO URINARY SYSTEM AND SEX HORMONES

N04BC07: Apomorphine

N04BC: Dopamine agonists

N04B: DOPAMINERGIC AGENTS

N04: ANTI-PARKINSON DRUGS

N: NERVOUS SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

267.32

Logarithm of the Partition Coefficient (xlogp)

2.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 10-20 min [4]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Clearance: The clearance of drug is 1440 L/h [6]
Elimination: 0.3% of drug is excreted from urine in the unchanged form [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.7 hours (15mg sublingual dose), and 50 minutes (intravenous dose) [6]
Metabolism: The drug is metabolized via the CYP2B6, 2C8, 3A4, and 3A5 [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.321 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.05% [8]
Vd: The volume of distribution (Vd) of drug is 123-404 L [6]
Water Solubility: The ability of drug to dissolve in water is measured as 20 mg/mL [5]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Adverse drug reaction	Not Available	FOS	OTJBUVWS	[9]
-----------

Chemical Identifiers

Formula: C17H17NO2
IUPAC Name: (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
Canonical SMILES: CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O
InChI: InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1
InChIKey: VMWNQDUVQKEIOC-CYBMUJFWSA-N

Cross-matching ID

PubChem CID: 6005
ChEBI ID: CHEBI:48538
CAS Number: 58-00-4
UNII: N21FAR7B4S
DrugBank ID: DB00714
TTD ID: D0H6QU
VARIDT ID: DR00890
INTEDE ID: DR0123

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Sulfotransferase 1A1 (SULT1A1)_{Main DME}	DEYWLRK	ST1A1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Drug Response	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Parkinson disease

ICD Disease Classification

8A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Sulfotransferase 1A1 (SULT1A1)	DME	SULT1A1	8.47E-01	3.57E-02	1.73E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Apomorphine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Pimavanserin.	Parkinsonism [8A00]	[12]
-----------

Coadministration of a Drug Treating the Disease Different from Apomorphine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[13]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Midostaurin.	Acute myeloid leukaemia [2A60]	[14]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Idarubicin.	Acute myeloid leukaemia [2A60]	[14]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Arn-509.	Acute myeloid leukaemia [2A60]	[15]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[16]
Memantine	DMD9WSC	Minor	Additive dopaminergic effects by the combination of Apomorphine and Memantine.	Alzheimer disease [8A20]	[15]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Apomorphine and Rivastigmine.	Alzheimer disease [8A20]	[14]
Donepezil	DMIYG7Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Apomorphine and Donepezil.	Alzheimer disease [8A20]	[14]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Apomorphine and Metronidazole.	Amoebiasis [1A36]	[17]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Apomorphine and Ivabradine.	Angina pectoris [BA40]	[15]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Bepridil.	Angina pectoris [BA40]	[14]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Dronedarone.	Angina pectoris [BA40]	[14]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[18]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Cilostazol.	Arterial occlusive disease [BD40]	[14]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Posaconazole.	Aspergillosis [1F20]	[14]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Levalbuterol.	Asthma [CA23]	[19]
Terbutaline	DMD4381	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Terbutaline.	Asthma [CA23]	[20]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Apomorphine and Pirbuterol.	Asthma [CA23]	[20]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Apomorphine and Salbutamol.	Asthma [CA23]	[19]
Formoterol	DMSOURV	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Formoterol.	Asthma [CA23]	[20]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[15]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[14]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[14]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Apomorphine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[14]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[14]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[14]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Loperamide.	Bowel habit change [ME05]	[22]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Eribulin.	Breast cancer [2C60-2C6Y]	[14]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Lapatinib.	Breast cancer [2C60-2C6Y]	[14]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Bosutinib.	Breast cancer [2C60-2C6Y]	[14]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[23]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Apomorphine and Isoproterenol.	Conduction disorder [BC63]	[19]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Halothane.	Corneal disease [9A76-9A78]	[14]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Sevoflurane.	Corneal disease [9A76-9A78]	[14]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Probucol.	Coronary atherosclerosis [BA80]	[14]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Clofazimine.	Crohn disease [DD70]	[24]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Mifepristone.	Cushing syndrome [5A70]	[14]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Pasireotide.	Cushing syndrome [5A70]	[14]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Osilodrostat.	Cushing syndrome [5A70]	[15]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Apomorphine and Ethanol.	Cystitis [GC00]	[25]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Sertraline.	Depression [6A70-6A7Z]	[14]
Trimipramine	DM1SC8M	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Trimipramine.	Depression [6A70-6A7Z]	[14]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Escitalopram.	Depression [6A70-6A7Z]	[14]
OPC-34712	DMHG57U	Moderate	Antagonize the effect of Apomorphine when combined with OPC-34712.	Depression [6A70-6A7Z]	[25]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Clomipramine.	Depression [6A70-6A7Z]	[14]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Doxepin.	Depression [6A70-6A7Z]	[14]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Maprotiline.	Depression [6A70-6A7Z]	[14]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[14]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Deutetrabenazine.	Dystonic disorder [8A02]	[26]
Ingrezza	DMVPLNC	Moderate	Additive CNS depression effects by the combination of Apomorphine and Ingrezza.	Dystonic disorder [8A02]	[27]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Solifenacin.	Functional bladder disorder [GC50]	[14]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Pentamidine.	Fungal infection [1F29-1F2F]	[14]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Ketoconazole.	Fungal infection [1F29-1F2F]	[14]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[14]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Propiomazine	DMKY8V1	Moderate	Antagonize the effect of Apomorphine when combined with Propiomazine.	Insomnia [7A00-7A0Z]	[25]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Apomorphine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[15]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Apomorphine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[14]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Crizotinib.	Lung cancer [2C25]	[28]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Ceritinib.	Lung cancer [2C25]	[14]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Osimertinib.	Lung cancer [2C25]	[29]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Selpercatinib.	Lung cancer [2C25]	[15]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Lumefantrine.	Malaria [1F40-1F45]	[17]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Halofantrine.	Malaria [1F40-1F45]	[30]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Hydroxychloroquine.	Malaria [1F40-1F45]	[31]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Primaquine.	Malaria [1F40-1F45]	[14]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[15]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Apomorphine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[32]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Vemurafenib.	Melanoma [2C30]	[14]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and LGX818.	Melanoma [2C30]	[33]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Apomorphine and Lasmiditan.	Migraine [8A80]	[34]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Panobinostat.	Multiple myeloma [2A83]	[35]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Apomorphine and Thalidomide.	Multiple myeloma [2A83]	[36]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Apomorphine and Siponimod.	Multiple sclerosis [8A40]	[17]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Apomorphine and Fingolimod.	Multiple sclerosis [8A40]	[14]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Apomorphine and Ozanimod.	Multiple sclerosis [8A40]	[37]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Romidepsin.	Mycosis fungoides [2B01]	[14]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[14]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[14]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Apomorphine when combined with Metoclopramide.	Nausea/vomiting [MD90]	[25]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Entrectinib.	Non-small cell lung cancer [2C25]	[17]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[15]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Rucaparib.	Ovarian cancer [2C73]	[14]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Buprenorphine.	Pain [MG30-MG3Z]	[14]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Triclabendazole.	Parasitic worm infestation [1F90]	[14]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Famotidine.	Peptic ulcer [DA61]	[17]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[38]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Lefamulin.	Pneumonia [CA40]	[39]
Ritodrine	DM4V6RL	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Ritodrine.	Preterm labour/delivery [JB00]	[20]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Degarelix.	Prostate cancer [2C82]	[15]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and ABIRATERONE.	Prostate cancer [2C82]	[15]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Enzalutamide.	Prostate cancer [2C82]	[15]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Bicalutamide.	Prostate cancer [2C82]	[15]
Levomepromazine	DMIKFEL	Moderate	Antagonize the effect of Apomorphine when combined with Levomepromazine.	Psychotic disorder [6A20-6A25]	[25]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[40]
Quetiapine	DM1N62C	Moderate	Antagonize the effect of Apomorphine when combined with Quetiapine.	Schizophrenia [6A20]	[25]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Mesoridazine.	Schizophrenia [6A20]	[14]
Aripiprazole	DM3NUMH	Moderate	Antagonize the effect of Apomorphine when combined with Aripiprazole.	Schizophrenia [6A20]	[25]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Iloperidone.	Schizophrenia [6A20]	[14]
Paliperidone	DM7NPJS	Moderate	Antagonize the effect of Apomorphine when combined with Paliperidone.	Schizophrenia [6A20]	[25]
Perphenazine	DMA4MRX	Moderate	Antagonize the effect of Apomorphine when combined with Perphenazine.	Schizophrenia [6A20]	[25]
Molindone	DMAH70G	Moderate	Antagonize the effect of Apomorphine when combined with Molindone.	Schizophrenia [6A20]	[25]
Thiothixene	DMDINC4	Moderate	Antagonize the effect of Apomorphine when combined with Thiothixene.	Schizophrenia [6A20]	[25]
Risperidone	DMN6DXL	Moderate	Antagonize the effect of Apomorphine when combined with Risperidone.	Schizophrenia [6A20]	[25]
Amisulpride	DMSJVAM	Major	Antagonize the effect of Apomorphine when combined with Amisulpride.	Schizophrenia [6A20]	[17]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Asenapine.	Schizophrenia [6A20]	[14]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Pimozide.	Schizophrenia [6A20]	[15]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[14]
LEE011	DMMX75K	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[14]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[14]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[15]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[14]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[14]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Lenvatinib.	Thyroid cancer [2D10]	[14]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Cabozantinib.	Thyroid cancer [2D10]	[15]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Papaverine.	Tonus and reflex abnormality [MB47]	[41]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Tacrolimus.	Transplant rejection [NE84]	[14]
Methdilazine	DMAUHQX	Moderate	Antagonize the effect of Apomorphine when combined with Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[25]
Trimeprazine	DMEMV9D	Moderate	Antagonize the effect of Apomorphine when combined with Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[25]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[14]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[14]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Apomorphine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[14]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Apomorphine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[14]
-----------


⏷ Show the Full List of 132 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 33).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Intranasal apomorphine. Nastech Pharmaceutical. IDrugs. 2004 May;7(5):483-8.
4	Jenner P, Katzenschlager R: Apomorphine - pharmacological properties and clinical trials in Parkinson's disease. Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S13-S21. doi: 10.1016/j.parkreldis.2016.12.003. Epub 2016 Dec 13.
5	BDDCS applied to over 900 drugs
6	FDA Approved Drug Products: Apomorphine Subcutaneous Injection
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
10	Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA. Synapse. 2009 May;63(5):378-89.
11	Sulfation of apomorphine by human sulfotransferases: evidence of a major role for the polymorphic phenol sulfotransferase, SULT1A1. Xenobiotica. 2003 Nov;33(11):1139-48.
12	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
13	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
14	Canadian Pharmacists Association.
15	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
17	Cerner Multum, Inc. "Australian Product Information.".
18	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
19	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
20	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
21	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
22	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
23	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
24	Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
25	Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
26	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
27	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
28	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
29	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
30	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
31	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
32	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
33	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
34	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
35	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
36	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
37	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
38	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
39	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
40	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
41	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]